Tom's talk on Ivermectin and Fenbendazole starts @ the 12-minute mark.
At the 17:40 mark, he shows a chart with the results of the study. Among the 122 cancer patients who completed a 6-month follow-up:
84.4% Reported clinical benefit. What benefit? They don't identify it. Why not?
48.4% Reported the strongest positive outcomes--either tumor shrinkage or no current evidence of disease. Okay, so this is something. Tumor shrinkage is good, as is " no current evidence of disease."
36.1% Reported their disease stayed about the same.
15.6% Reported disease progression. Okay, not good, not good at all.
The study began with 197 cancer patients and 122 completed follow-up. Patients were prescribed capsules containing 25 mg of Ivermectin and 250 mg of Menbendazole. They took up to 4 capsules per day, according to Physicians recommendation.
75 patients, or 40% of patients on we have no information about what happened to them maybe they all died or maybe they had horrible side effects and stopped taking it or maybe nothing happened to them and they ran out of money or maybe they were all cured of cancer and so they didn't want to do the follow-up questionnaire. Many more possibilities could be true, but we have no way of knowing that. Patients were prescribed this dose, 4 capsules a day.
Tom claims that the descriptor of "Self-Reported Cancer Outcomes" means that nobody was checking or there was no testing done to see whether these were accurate. Everything in this so-called "study" is self-reported. In other words the people self-reported without any seemingly attempt to check whether it was accurate or not; that they, in fact, did have this disease that they said they did and then they self-reported without any lab tests, without any x-rays, without any studies, without any examinations, just self-reported how they had done. [Okay, so how would they know that their tumors shrank or that the progression of their disease stabilized?].
Of the 84.4% who benefited, 32.8% had no current evidence of disease; 15.6% had regression of the disease; and in 36.1% of patients, their disease stabilized.
21:32. Presents the authors of the study.
For a medication that's a 1% the cost of chemotherapy, it showed a remarkable efficacy rate:
84.4% reported clinical benefit defined as improved or stabilization of disease.
Nearly 1 in 2 reported the strongest positive outcomes: tumor shrinkage or no evidence of disease.
15.6% reported progression of disease.
23:02. Baseline cancer, this is the type of cancer, and again when they say this was actively spreading or stable this is simply the patient self-reporting, no tests done, no doctor checking, no lab tests, no x-rays, no radiographic studies, this was just patient self-reporting, where their status was.
He's referencing this study here:
